Back to results
US 8,592,364 B2Granted
CCR7 ligand delivery and co-delivery in immunotherapy
AssigneeEcole Polytechnique Federale De Lausanne (Epfl)
InventorsMelody A. Swartz, Jeffrey A. Hubbell, Alice A. Tomei, Jacqueline D. Shields, Iraklis Kourtis
Life of this patent
Estimating the term…
Abstract
Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described.
Claims26
A method of treating a human patient receiving a tissue implant to achieve immunotolerance to the implant, the implant having exogenous antigens, the method comprising:
- administering a chemokine to the human patient to establish adaptive immune system treatment of the exogenous antigens as self-antigens to thereby achieve immunotolerance to the implant, the chemokine being chosen from the group consisting of CC-chemokine ligand-19 (CCL19), CC-chemokine ligand-21 (CCL21), and combinations thereof.
A method of inducing immunotolerization for a tissue implanted in a human patient, said tissue having exogenous antigens, the method comprising
- administering a chemokine to the human patient in combination with the tissue, with the chemokine being administered in an amount effective to establish adaptive immune system treatment of the exogenous antigens as self-antigens to thereby achieve immunotolerization to the tissue chosen from the group consisting of CC-chemokine ligand-19 (CCL19), CC-chemokine ligand-21 (CCL21), and combinations thereof.
Dependencies are inferred from the claim text.